Hennion & Walsh Asset Management, Inc. Krystal Biotech, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.84 Billion
- Q1 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 33,154 shares of KRYS stock, worth $5.89 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
33,154
Previous 31,398
5.59%
Holding current value
$5.89 Million
Previous $3.9 Million
51.45%
% of portfolio
0.32%
Previous 0.22%
Shares
10 transactions
Others Institutions Holding KRYS
# of Institutions
262Shares Held
21.5MCall Options Held
462KPut Options Held
723K-
Avoro Capital Advisors LLC New York, NY2.56MShares$454 Million5.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$432 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$321 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.51MShares$268 Million10.58% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$176 Million9.23% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.56B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...